TNFerade(TM) Phase III Data Presented at ASCO
...-care (SOC) arm compared to the patients receiving soc
alone (Hazard Ratio = 0.75; 95% Confidence Interva...velopment commented on the poster, noting, "In the soc
patients, 75% of the patients died within approximately 11.8 months. However, in the TNFerade plus soc
group, 75% of the patients did not die until appro...
Clinical Update - Debio 025 in Hepatitis C
...io 025. Three
different triple combination regimens will be compared to the soc
The Company aims to evaluate whether there is an increase in the... < 10 U/mL 24
weeks after treatment end) with Debio 025, compared to the soc
trial will include 272 treatment-naive chronic HCV genotype ...
Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
...22 of 25)
patients receiving R7128 1000mg BID with soc
for 4 weeks achieved
undetectable HCV RNA levels (...1000mg BID with SOC
was comparable to placebo with soc
in Cohort 3. One patient was
discontinued from the...en at the dose of 500mg,
R7128 in combination with soc
has demonstrated a greater percentage of RVR
New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
...gh blockade of angiotensin II receptors. J Am soc
Hypertension 2008;2(3);165-172 2. Smith, Ronalde...gh blockade of angiotensin II receptors. J Am soc
Hypertension 2008;2(3);165-172 3. Intengan, HD e...gh blockade of angiotensin II receptors. J Am soc
Hypertension 2008;2(3);165-172 20. Smith, Ronalde...
Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
...nide followed by 36 weeks of nitazoxanide plus soc
with peginterferon plus ribavirin (a triple regime...ts, combination therapy with nitazoxanide plus soc
resulted in a SVR24 rate of 79%, compared with 50% for those treated with soc
without nitazoxanide (P=0.023). When nitazoxanide ...
New Pfizer Oncology Data Across Numerous Cancer Types to be
Presented at ASCO
second and later lines, as both a single agent and in various
combinations, including: combined with standard of care (SOC)
chemotherapies versus soc
chemotherapies alone and combined with
SOC chemotherapies versus other targeted therapies. The studies
will evaluate sunitinib malate in patients with...
GenVec Announces Update of Safety and Efficacy Data from Pivotal
Phase II/III PACT Study of TNFerade at ASCO
...val was 19.3 months for
patients in the TNFerade + soc
arm versus 11.1 months for patients
receiving stan...atients in the TNFerade +
SOC group and 11% in the soc
The safety analysis indicated that there .... Seventy percent of patients receiving TNFerade + soc
78% of those receiving...
New Study Shows That telmisartan has Greater Renoprotective
Potential Thanlosartan in Hypertensive Patients With Type 2
(5) Yue JL et al.
Forecast of the number of patients with end-stage renal
disease in the United States to the year 2010. J Am soc
Nephrol. 2001; 12:2735-8.
(6) Bakris G et al.
Comparative long term effects of two AT1 receptor blockers on
proteinuria in p...